Drugs / Bivalent Subtype C gp120/MF59
last change Nov 2021 re-read 2 minutes ago

Bivalent Subtype C gp120/MF59

Developed for
HIV infectious disease

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02968849 Comparator Oct 2016 → Nov 2021 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Bivalent Subtype C gp120/MF59 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02968849
Route Intramuscular “delivered IM” NCT02968849